Research - Synergy Pharma (SGYP) fell briefly this morning when Phase V Research reported that Ironwood’s (IRWD) Linzess (linaclotide) is producing significant rates of adverse events in real world use, and that the drug may even be too dangerous to remain on the market.
Research - Bluebird bio (BLUE) released interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) this morning and will present the results at AAN today, evaluating Lenti-D in cerebral adrenoleukodystrophy (CALD), known colloquially as Lorenzo’s Oil disease.
Research - Every stock has its day. Ariad Pharmaceuticals (ARIA) has had a few. From safety issues with its only marketed product Iclusig in 2014, that sent the stock reeling from $20 to $2, to repeat takeover rumors over the last few years that sent the stock soaring.